Targets › CRAF
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2028.
Open in Phaseline: the race on CRAF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institut de Recherches Internationales Servier | S241656 RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) | BRAF, CRAF, KRAS, NRAS | Phase 1 | Non-small Cell Lung Cancer | Jun 2028 |
Non-small Cell Lung Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.